Related Experiment Video

Updated: Aug 20, 2026

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

Heart and mind: (2) psychotropic and cardiovascular therapeutics

S U Shah1, Z Iqbal, A White

  • 1Department of Cardiology, Ysbyty Gwynedd, Bangor, North Wales, UK. saeedshah@miranshah.freeserve.co.uk

Postgraduate Medical Journal
|January 11, 2005
PubMed

Insights

Psychiatric conditions like depression and anxiety are common in cardiovascular disease patients, yet often unrecognized. This review examines psychotropic drug interactions and safe use in managing these coexisting conditions.

Area of Science:

  • Cardiology
  • Psychiatry
  • Clinical Pharmacology

Background:

  • Psychiatric conditions, including anxiety, panic disorder, and depression, are frequently observed in patients with cardiovascular disease (CVD), such as coronary heart disease and hypertension.
  • There is a notable underdiagnosis and underrecognition of these psychiatric comorbidities in both primary care and hospital medical settings.
  • The co-prescription of psychotropic medications for psychiatric conditions in patients with CVD raises concerns regarding potential drug interactions and systemic effects.

Purpose of the Study:

  • To review the evidence on the interactions between psychotropic drugs and cardiovascular medications.
  • To discuss the relative effects of these medications on both psychiatric and cardiovascular systems.
  • To summarize recommendations for the safe and effective use of psychotropic drugs in patients with coexisting cardiovascular disease.

Main Methods:

  • Literature review of existing evidence on the association between psychiatric morbidity and cardiovascular disease.
  • Analysis of drug interactions between commonly prescribed psychotropic and cardiovascular medications.
  • Synthesis of current recommendations for managing coexisting psychiatric and cardiovascular conditions.

Main Results:

  • Psychiatric disorders are prevalent in patients with coronary heart disease and hypertension.
  • Poor recognition of psychiatric conditions in clinical practice is a significant issue.
  • Drug interactions between psychotropic and cardiovascular medications require careful consideration.

Conclusions:

  • Effective management of patients with coexisting psychiatric and cardiovascular conditions necessitates understanding drug interactions.
  • Evidence-based recommendations support the safe use of psychotropic medications in this patient population.
  • Improved recognition and management of psychiatric comorbidities can enhance overall patient outcomes.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...